Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 1—January 2023

Burden of Postinfectious Symptoms after Acute Dengue, Vietnam

Dong Thi Hoai Tam1, Hannah Clapham1Comments to Author , Elisabeth Giger, Nguyen Tan Thanh Kieu, Nguyen Tran Nam, Dinh Thi Tri Hong, Banh Thi Nuoi, Nguyen Thi Hong Cam, Nguyen Than Ha Quyen, Hugo C. Turner, Thomas Jaenisch, Cameron P. Simmons, Phung Khanh Lam, and Bridget Wills
Author affiliations: Oxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam (D.T.H. Tam, E. Giger, N.T.T. Kieu, D.T.T. Hong, B.T. Nuoi, N.T.H. Cam, N.T.H. Quyen, P.K. Lam, B. Wills); University of Oxford, Oxford, England, UK (H. Clapham, B. Wills); National University of Singapore and National University Health System, Singapore (H. Clapham); City Children’s Hospital, Ho Chi Minh City (N.T. Nam); Imperial College London, London, England, UK (H.C. Turner); Heidelberg University Hospital, Heidelberg, Germany (T. Jaenisch); Colorado School of Public Health, Aurora, Colorado, USA (T. Jaenisch); Monash University, Melbourne, Victoria, Australia (C.P. Simmons); University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City (K. Lam)

Cite This Article


We assessed predominantly pediatric patients in Vietnam with dengue and other febrile illness 3 months after acute illness. Among dengue patients, 47% reported >1 postacute symptom. Most resolved by 3 months, but alopecia and vision problems often persisted. Our findings provide additional evidence on postacute dengue burden and confirm children are affected.

Dengue is a mosquitoborne viral infection found across much of the tropical and subtropical world. Most infections are asymptomatic or paucisymptomatic. Acute symptoms range from an influenza-like self-limited febrile illness to, in a small proportion of cases, severe and complicated disease that can prove fatal (1). In total, 4 dengue viral serotypes (DENV-1–4) exist; severe disease rarely occurs during the first exposure to any serotype (i.e., a primary infection) but is more likely to occur during a subsequent infection with a different serotype (i.e., a secondary infection).

The symptoms of acute dengue are generally understood to resolve after 1–2 weeks, but the potential for persistent or delayed symptoms has received increasing attention in recent years. However, few formal studies have been published, and these studies have reported a range of symptoms and frequencies (28). A recent review summarizing this literature showed a substantial proportion of persons experienced some kind of postacute symptoms; the proportion decreased over time after infection (9), and 24% reported notable fatigue (4).

The Study

We report on postinfectious symptoms in 247 predominantly pediatric patients from Vietnam 3 months after an acute febrile illness; 200 of them had dengue (Appendix). After acute dengue, we observed a broad spectrum of postviral symptoms ranging from fatigue, joint pain, and muscle pain to vision problems and hair loss (Table). We report ≈8% patients experienced fatigue, consistent with a study in Singapore reporting 9% (3), but lower than the 24% in another Singapore study (2) and the 28% reported from Cuba (4). The Cuba study also reported headaches in 15% of patients compared with our estimate of 4%, whereas a recent study of 79 dengue-infected persons in Mexico indicated that 38% reported headaches in the second week after onset of fever, which dropped to 8% at 6–8 months (10). Our estimate of 47% of persons experiencing >1 symptom is higher than the 8.5% observed in Peru (8) but lower than the 65% experiencing >1 persistent symptom observed in Brazil (6). In general, the sample sizes were small in all studies, and the study methods or timeframes after infection differed.

Symptoms have previously been associated with older age, but in our study the only symptom observed to be more likely in adults than children was joint pain (Appendix Table 2). Other studies have noted a higher frequency of symptoms in female than male patients (2,5,6,8). We noted this difference for alopecia and joint pain only; few men (3%) experienced either of these symptoms compared with ≈30% of women (Appendix Table 3). As for most other studies assessing the relationship between postinfectious symptoms and disease severity (2,5), we did not observe any relationship between symptoms after infection and disease severity during acute infection (Appendix Table 4). The numbers were small, but our study indicated worse symptoms (loss of appetite, blurred vision, and concentration problems) might be more likely after DENV-3 infection than infection with other serotypes (Appendix Table 4). This suggestion remained after controlling for disease severity and primary or secondary infection. Whether postacute symptoms vary by serotype is a possible line of future study.

The alopecia we report in our study (25/200 [13%] in dengue vs. 2/47 [4%] in other febrile illness [OFI]) has been observed previously, at a much lower rate in 1 study in Brazil (7) and at a similar rate in a recent study from Mexico (10). Alopecia after dengue has been noted in 1 case report (11). We identified alopecia in our study only in the category of other symptoms, and it was reported by patients without specific prompting, so this result is striking. Vision problems associated with dengue have previously been reported but mainly during the acute phase or soon afterwards (12,13). In our study, we saw that these symptoms can persist for several months or start much later after infection (Appendix Table 6), which was also seen in the recent study in Mexico (10). We found no association between specific symptoms during acute infection and afterwards (Appendix Table 5).

For many of the symptoms we report, occurrence rates were similar in the dengue and OFI groups (Table). Although the OFI group was relatively small and we do not have specific diagnoses for these persons, the data suggest that the late effects of dengue are not dissimilar to those experienced after other acute febrile illnesses. Our enrollment criteria and the fact that most patients recovered without additional therapy suggest a likely viral etiology; the pathogens causing disease in the control groups are likely to be quite variable between geographic locations, possibly explaining our lower rate of postacute consequences in the dengue group compared with the OFI groups in other studies (3,8).

Another potentially interesting observation was the lower rate of other illnesses experienced after the initial acute episode in the dengue group compared with the control group (33/200 [16.5%] vs. 14/47 [30%]) (Table). This lower rate might suggest some nonspecific immune modulation after dengue that is protective, or the rate in the other group could be higher than usual because of an effect of the other febrile illnesses.


Understanding the burden of postacute symptoms is key to calculating the overall disease burden of dengue (14). A recent review estimated that the economic cost of persistent symptoms after dengue in Mexico alone was US $22.6 million (2012 prices) (9). In those estimates, the authors assumed symptoms were only experienced in adults because they saw an increase in the proportion of persons experiencing symptoms with age. We clearly show that children also experience postacute symptoms. In countries such as Vietnam, where much of the acute disease occurs in children, including postacute consequences in this group might change burden estimates considerably. In the Global Burden of Disease 2013 Study, 44% of the estimated total number of disability-adjusted life-years (DALYs) lost because of dengue was attributed to persistent symptoms (15). In recent Global Burden of Disease estimates, 8.5% of cases are assumed to experience acute consequences and are given a disability weight for chronic fatigue lasting for 6 months. In the context of our results, 8.5% might be a fairly realistic estimate; however, 100% of our patients had returned to work or normal daily life by 3 months postinfection. How accurately the infectious disease–postacute consequences disability weight currently being used represents the severity of postacute consequences is uncertain. We also observed that most symptoms lasted <1 month, suggesting 6 months is an overestimate of the duration of postacute consequences for this setting. This observation highlights the need for further research in this area because such burden calculations can influence public health priority-setting and funding decisions.

In summary, we have provided estimates of the proportion of dengue infections, mainly in children, that result in longer-term symptoms in a population in Vietnam. In addition to previously observed tiredness and joint pain, we have provided evidence for 2 longer-term symptoms, hair loss and vision problems. Further work in other settings should assess whether these symptoms are seen elsewhere. We also provide evidence that children experience long-term symptoms after dengue. This work is informative to the estimates of the burden of dengue and suggests additional information about the likely recovery path that could be given to patients when discharged after acute dengue.

About the Author

Dr. Tam was until recently associate professor in the infectious diseases department of the University of Medicine at Ho Chi Minh City, Vietnam. Since retiring, she has continued her scientific research by contributing to many dengue clinical studies at the Oxford University Clinical Research Unit, Ho Chi Minh City. Dr. Clapham is an assistant professor who researches infectious disease dynamics at the Saw Swee Hock School of Public Health, National University of Singapore. Previously, she was head of the mathematical modelling group at the Oxford University Clinical Research Unit, Ho Chi Minh City.



This work was supported by the European Union’s Seventh Framework Programme for research, technological development and demonstration (grant FP7-281803 IDAMS;; publication reference number IDAMS: 57) as well as core grant support to the Oxford University Clinical Research Unit from Wellcome (grant code 106680/B/14/Z). H.C.T. acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. iDSI is funded by the Bill and Melinda Gates Foundation [OPP1134345], the UK’s Department for International Development, and the Rockefeller Foundation.



  1. Halstead  SB. Dengue. Lancet. 2007;370:164452. DOIPubMedGoogle Scholar
  2. Seet  RCS, Quek  AML, Lim  ECH. Post-infectious fatigue syndrome in dengue infection. J Clin Virol. 2007;38:16. DOIPubMedGoogle Scholar
  3. Low  JGH, Ooi  E-E, Tolfvenstam  T, Leo  YS, Hibberd  ML, Ng  LC, et al. Early Dengue infection and outcome study (EDEN) - study design and preliminary findings. Ann Acad Med Singap. 2006;35:7839.PubMedGoogle Scholar
  4. González  D, Martínez  R, Castro  O, Serrano  T, Portela  D, Vazquez  S, et al. Evaluation of some clinical, humoral and imagenological parameters in patients of dengue haemorrhagic fever six months after acute illness. Dengue Bull. 2005;29:537.
  5. García  G, González  N, Pérez  AB, Sierra  B, Aguirre  E, Rizo  D, et al. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis. 2011;15:e3843. DOIPubMedGoogle Scholar
  6. Teixeira  LA, Lopes  JSM, Martins  AG, Campos  FA, Miranzi  SS, Nascentes  GA. [Persistence of dengue symptoms in patients in Uberaba, Minas Gerais State, Brazil] [in Portuguese]. Cad Saude Publica. 2010;26:62430. DOIPubMedGoogle Scholar
  7. Tristão-Sá  R, Kubelka  CF, Zandonade  E, Zagne  SM, Rocha  NS, Zagne  LO, et al. Clinical and hepatic evaluation in adult dengue patients: a prospective two-month cohort study. Rev Soc Bras Med Trop. 2012;45:67581. DOIPubMedGoogle Scholar
  8. Halsey  ES, Williams  M, Laguna-Torres  VA, Vilcarromero  S, Ocaña  V, Kochel  TJ, et al. Occurrence and correlates of symptom persistence following acute dengue fever in Peru. Am J Trop Med Hyg. 2014;90:44956. DOIPubMedGoogle Scholar
  9. Tiga  DC, Undurraga  EA, Ramos-Castañeda  J, Martínez-Vega  RA, Tschampl  CA, Shepard  DS. Persistent symptoms of dengue: estimates of the incremental disease and economic burden in Mexico. Am J Trop Med Hyg. 2016;94:10859. DOIPubMedGoogle Scholar
  10. Tiga-Loza  DC, Martínez-Vega  RA, Undurraga  EA, Tschampl  CA, Shepard  DS, Ramos-Castañeda  J. Persistence of symptoms in dengue patients: a clinical cohort study. Trans R Soc Trop Med Hyg. 2020;114:35564. DOIPubMedGoogle Scholar
  11. Hitani  A, Yamaya  W, To  M, Kano  I, Honda-Hosono  N, Takasaki  T, et al. A case of dengue fever and subsequent long-lasting depression accompanied by alopecia in a Japanese traveler returning from Bali, Indonesia [in Japanese]. Kansenshogaku Zasshi. 2015;89:27982. DOIPubMedGoogle Scholar
  12. Seet  RCS, Quek  AML, Lim  ECH. Symptoms and risk factors of ocular complications following dengue infection. J Clin Virol. 2007;38:1015. DOIPubMedGoogle Scholar
  13. Chee  E, Sims  JL, Jap  A, Tan  BH, Oh  H, Chee  S-P. Comparison of prevalence of dengue maculopathy during two epidemics with differing predominant serotypes. Am J Ophthalmol. 2009;148:9103. DOIPubMedGoogle Scholar
  14. Hung  TM, Wills  B, Clapham  HE, Yacoub  S, Turner  HC. The uncertainty surrounding the burden of post-acute consequences of dengue infection. Trends Parasitol. 2019;35:6736. DOIPubMedGoogle Scholar
  15. Vos  T, Barber  RM, Bell  B, Bertozzi-Villa  A, Biryukov  S, Bolliger  I, et al.; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743800. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2901.220838

Original Publication Date: December 16, 2022

1These first authors contributed equally to this article.

Table of Contents – Volume 29, Number 1—January 2023

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Hannah Clapham, Saw Swee Hock School of Public Health, National University of Singapore, MD1, 12 Science Dr 2, 117549, Singapore

Send To

10000 character(s) remaining.


Page created: November 17, 2022
Page updated: December 22, 2022
Page reviewed: December 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.